DLEU1

Summary

DLEU1 (deleted in lymphocytic leukemia 1, HGNC:13747) is a long non-coding RNA gene on chromosome 13q14.2-q14.3. May act as a tumor suppressor.

At a glance

• Gene type: non-coding (lncRNA) — no protein product; not a drug target. Variant/disease associations are omitted (they would be positional, from an overlapping protein-coding gene).

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:13747
Approved symbol	DLEU1
Name	deleted in lymphocytic leukemia 1
Location	13q14.2-q14.3
Locus type	RNA, long non-coding
Status	Approved
Aliases	LEU1, XTP6, NCRNA00021, LINC00021, BCMS1
Ensembl gene	ENSG00000176124
Ensembl biotype	lncRNA
OMIM	605765
Entrez	10301
RNAcentral	URS000075DA5A — lncRNA, 2904 nt, 1 organism(s)

Gene structure

Transcript identifiers

Ensembl transcripts: 57 — 57 lncRNA

ENST00000413510, ENST00000460525, ENST00000461527, ENST00000462427, ENST00000463357, ENST00000463474, ENST00000467721, ENST00000468168, ENST00000468522, ENST00000469095, ENST00000469127, ENST00000469754, ENST00000470593, ENST00000470726, ENST00000472136, ENST00000473075, ENST00000474630, ENST00000475913, ENST00000476738, ENST00000478860, ENST00000479420, ENST00000483169, ENST00000483444, ENST00000484529, ENST00000484606, ENST00000484869, ENST00000485007, ENST00000486895, ENST00000489542, ENST00000490577, ENST00000491341, ENST00000491482, ENST00000491615, ENST00000498557, ENST00000647700, ENST00000650910, ENST00000650996, ENST00000652753, ENST00000655550, ENST00000658634, ENST00000659280, ENST00000668174, ENST00000671384, ENST00000717734, ENST00000732841, ENST00000732842, ENST00000732843, ENST00000790413, ENST00000790414, ENST00000848549, ENST00000848550, ENST00000848551, ENST00000848552, ENST00000848553, ENST00000848554, ENST00000848555, ENST00000848556

RefSeq mRNA: 0 — MANE Select: None

Canonical transcript exons

ENST00000413510 — 5 exons

Exon	Start	End
ENSE00001684348	50807855	50807986
ENSE00001693384	50848537	50849905
ENSE00001707328	50808540	50808706
ENSE00001763456	50840028	50840094
ENSE00003493966	50818521	50818592

Expression profiles

Bgee: expression breadth ubiquitous, 162 present calls, max score 91.03.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 12.2271 / max 123.6232, expressed in 1773 samples.

FANTOM5 promoters (11 alternative TSS)

Promoter ID	TPM avg	Samples expressed
135139	11.3923	1684
135163	0.6612	244
135162	0.1588	109
135166	0.1466	16
135167	0.0839	12
135169	0.0375	6
135168	0.0349	8
135171	0.0153	4
135157	0.0148	5
135170	0.0056	3

Top tissues by expression

247 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	91.03	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	90.20	gold quality
islet of Langerhans	UBERON:0000006	87.31	gold quality
sural nerve	UBERON:0015488	87.06	gold quality
colonic epithelium	UBERON:0000397	84.97	gold quality
ventricular zone	UBERON:0003053	82.87	gold quality
calcaneal tendon	UBERON:0003701	82.69	gold quality
adrenal tissue	UBERON:0018303	81.20	gold quality
monocyte	CL:0000576	81.10	gold quality
leukocyte	CL:0000738	81.01	gold quality
bone marrow cell	CL:0002092	80.84	gold quality
hindlimb stylopod muscle	UBERON:0004252	79.19	gold quality
left testis	UBERON:0004533	78.75	gold quality
right testis	UBERON:0004534	78.46	gold quality
mucosa of transverse colon	UBERON:0004991	77.98	gold quality
rectum	UBERON:0001052	77.88	gold quality
ganglionic eminence	UBERON:0004023	77.78	gold quality
testis	UBERON:0000473	77.56	gold quality
muscle of leg	UBERON:0001383	76.79	gold quality
granulocyte	CL:0000094	76.53	gold quality
esophagus mucosa	UBERON:0002469	76.39	gold quality
gastrocnemius	UBERON:0001388	76.19	gold quality
right atrium auricular region	UBERON:0006631	76.05	gold quality
heart left ventricle	UBERON:0002084	75.64	gold quality
pancreas	UBERON:0001264	75.50	gold quality
lower esophagus mucosa	UBERON:0035834	75.21	gold quality
esophagus	UBERON:0001043	75.20	gold quality
smooth muscle tissue	UBERON:0001135	75.17	gold quality
cardiac atrium	UBERON:0002081	75.14	gold quality
right lobe of liver	UBERON:0001114	75.13	gold quality

Single-cell (SCXA)

Detected in 4 experiment(s), a significant marker in 4.

Experiment	Marker?	Max mean expression
E-GEOD-180759	yes	2090.07
E-HCAD-35	yes	43.29
E-HCAD-25	yes	19.91
E-ANND-3	yes	7.07

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): E2F4, MYC

Literature-anchored findings (GeneRIF, showing 31)

• Leu1 seems to be only one of the smallest splicing variants of a large gene termed BCMS. (PMID:11406609)
• propose that the underlying pathomechanism of CLL involves co-regulation of miRNA genes miR-16-1 and miR-15a by the two long non-coding RNA genes DLEU1 and DLEU2. (PMID:19347735)
• we describe an example where two lncRNA genes (DLEU1 and DLEU2) are epigenetically deregulated together with a cluster of neighboring protein-coding tumor suppressor genes in almost all patients suffering from chronic lymphocytic leukemia (PMID:23593011)
• Data suggest that DLEU1 may in part function as a tumor suppressor gene and confer chemoimmunotherapy resistance in children and adolescents with Burkitt lymphoma. (PMID:28427156)
• It has been suggested that through interaction with miR-490-3p DLEU1 may influence the expression of CDK1, CCND1 and SMARCD1 protein, subsequently promoting the development and progression of ovarian carcinoma. (PMID:28598010)
• In two cohorts with available data, we identified one intronic SNP (rs13361131) in myosin X gene (MYO10) associated with C17:0 level (P = 1.37x10-8), and two intronic SNP (rs12874278 and rs17363566) in deleted in lymphocytic leukemia 1 (DLEU1) region associated with C19:0 level (P = 7.07x10-9) (PMID:29738550)
• lncRNA DLEU1 combines with mTOR and then increases the expression of PI3K/AKT/mTOR pathway to promote endometrial carcinoma tumorigenesis and progression. Silence of mTOR after up-regulation of lncRNA DLEU1 resulted in decrease of cell viability, migration, and invasion and increase of apoptosis. (PMID:29745433)
• Our findings indicate that DLEU1 contributes to endometrial cancer development by sponging miR-490 to regulate SP1 expression (PMID:30001771)
• Data found that DLEU1 was up-regulated in CRC tissues. Its overexpression promoted CRC cell proliferation, migration and invasion. DLEU1 co-localized with SMARCA1 in CRC, and is indispensable for the deposition of SMARCA1 at the promoter of KPNA3 gene. Collectively, DLEU1 recruited SMARCA1 to epigenetically activate KPNA3, thereby promoting proliferation and migration in colorectal cancer. (PMID:30098595)
• Long noncoding RNA DLEU1 aggravates pancreatic ductal adenocarcinoma carcinogenesis via the miR-381/CXCR4 (PMID:30382579)
• DLEU1 promoted tumorigenesis and progression of non-small cell lung cancer. (PMID:30551552)
• Up regulation of DLEU1 expression by epigenetic modification promotes tumorigenesis in human cancer (PMID:30793303)
• Small interfering RNA demonstrated that silencing DLEU1 downregulated TRAF4. The viability of Glioblastoma multiforme (GBM)cells was significantly decreased following RNA interference with DLEU1 and TRAF4 production. (PMID:31257517)
• Long noncoding RNA DLEU1 aggravates osteosarcoma carcinogenesis via regulating the miR-671-5p/DDX5 axis (PMID:31379208)
• these results indicated a prooncogenic role of DLEU1 in the progression and development of renal cell carcinoma via modulation of the Akt pathway and EMT phenotype. (PMID:31702026)
• SP1-DLEU1-miR-4429 feedback loop promotes cell proliferative and anti-apoptotic abilities in human glioblastoma. (PMID:31713587)
• LncRNA DLEU1/microRNA-300/RAB22A axis regulates migration and invasion of breast cancer cells. (PMID:31841195)
• [Deleted in lymphocytic leukemia 1 promoted proliferation and apoptosis of nephroblastoma cells through regulating miR-513a-5p and RANBP2 pathway]. (PMID:33113626)
• Silencing of lncRNA DLEU1 inhibits tumorigenesis of ovarian cancer via regulating miR-429/TFAP2A axis. (PMID:33170430)
• Knockdown of lncRNA DLEU1 inhibits the tumorigenesis of oral squamous cell carcinoma via regulation of miR1495p/CDK6 axis. (PMID:33880596)
• DLEU1 promotes oral squamous cell carcinoma progression by activating interferon-stimulated genes. (PMID:34650128)
• Overexpression of lncRNA DLEU1 in Gastric Cancer Tissues Compared to Adjacent Non-Tumor Tissues. (PMID:34738190)
• LncRNA DLEU1 is overexpressed in premature ovarian failure and sponges miR-146b-5p to increase granulosa cell apoptosis. (PMID:34740384)
• Survivalrelated DLEU1 is associated with HPV infection status and serves as a biomarker in HPVinfected cervical cancer. (PMID:35014679)
• DLEU1 promotes cell survival by preventing DYNLL1 degradation in esophageal squamous cell carcinoma. (PMID:35619131)
• lncRNA DLEU1 Modulates Proliferation, Inflammation, and Extracellular Matrix Degradation of Chondrocytes through Regulating miR-671-5p. (PMID:35647200)
• Long non-coding RNA DLEU1 promotes malignancy of breast cancer by acting as an indispensable coactivator for HIF-1alpha-induced transcription of CKAP2. (PMID:35853854)
• YY1-induced DLEU1/miR-149-5p Promotes Malignant Biological Behavior of Cholangiocarcinoma through Upregulating YAP1/TEAD2/SOX2. (PMID:35864972)
• LncRNA DLEU1 facilitates the progression of oral squamous cell carcinoma by miR-126-5p/GAB1 axis. (PMID:36039933)
• [Prognostic value and mechanism of long non-coding RNA DLEU1 in osteosarcoma]. (PMID:37366099)
• LncRNA DLEU1 promotes angiogenesis in diabetic foot ulcer wound healing by regulating miR-96-5p. (PMID:37515685)

Cross-species orthologs

0 orthologs

Protein

Non-coding RNA — no protein product; not a drug target.

Function

No curated pathway, Gene-Ontology, or interaction data.

Disease & clinical

No curated disease, variant, or cancer-driver associations.

Drugs & pharmacology

No drug or pharmacology data — not an established drug target.